In a phase 1 trial (NCT03019055), of 22 patients receiving CD19 and CD20-targeted CAR-T cells, 14 (64%) achieved CR, one (5%) developed grade 3–4 CRS, and three (14%) developed grade 3–4 neurotoxicity, suggesting that this therapeutic approach has good potential (CRS, American Society for Transplantation and Cellular Therapy criteria; other adverse events, CTCAE v5.0) [51]. This evidence concerns the gene CD19 and congenital rubella syndrome.